<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475616</url>
  </required_header>
  <id_info>
    <org_study_id>PCO001US</org_study_id>
    <nct_id>NCT02475616</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study of PCO371 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Single Ascending Oral Dose Study To Evaluate Safety, Tolerability And Pharmacokinetics Of PCO371 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <brief_summary>
    <textblock>
      This is a single-center, placebo-controlled, randomized, double-blind, dose-escalation study
      to evaluate safety, tolerability, and PK of a single oral (PO) administration of PCO371 in
      healthy adult males.

      Caucasian and Japanese subjects will be randomized to receive either PCO371 or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by adverse events</measure>
    <time_frame>15days or 22days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by temperature</measure>
    <time_frame>15days or 22days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by systolic blood pressure, diastolic blood pressure</measure>
    <time_frame>15days or 22days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by pulse rate</measure>
    <time_frame>15days or 22days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by physical findings examinations, including weight</measure>
    <time_frame>15days or 22days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Laboratory test values</measure>
    <time_frame>15days or 22days</time_frame>
    <description>Laboratory tests include hematology, biochemistry, urine analysis and coagulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by ECGs</measure>
    <time_frame>15days or 22days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations and PK parameters (AUC, Cmax, Tmax, total clearance, volume of distribution and T1/2) of PCO371 in healthy male volunteers</measure>
    <time_frame>15days or 22days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentrations and PK parameters (cumulative excretion and renal clearance) of PCO371</measure>
    <time_frame>15days or 22days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Time profile of serum/plasma concentrations in albumin-corrected total calcium (Ca); 25-hydroxy vitamin D (vit D), 1,25-dihydroxy vit D, and 24,25-dihydroxy vit D; phosphate; magnesium; and cAMP of PCO371</measure>
    <time_frame>15days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Urinary excretion of Ca, phosphate, magnesium, protein, sodium, potassium, chloride, and cAMP of PCO371</measure>
    <time_frame>15days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Nephrogenous cAMP of PCO371</measure>
    <time_frame>15days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PCO371</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of PCO371</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCO371</intervention_name>
    <arm_group_label>PCO371</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged 18 to 45 years.

          -  Caucasian(BMI 18-30 mg/kg2) or first generation japanese(BMI 18-25kg/m2)

          -  Able and willing to abide by the protocol

        Exclusion Criteria:

          -  Evidence of any medical condition that could affect renal, hepatic, or cardiopulmonary
             functions.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ger Rikken</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wcct Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

